Almost a month back, the European Union (EU) issued marketing authorization for the Ebola vaccine to combat the infection among adults, and the FDA has approved it in the US last week. Although Ebola-related cases across the nation are very rare, the director of the Center for Biologics Evaluation and Research at FDA Peter Marks stated that possible Ebola outbreaks in the future could be prevented through vaccination.
Several studies & surveys are favoring Ebola vaccine approval, of which one includes a case study of 900 subjects in the US, Spain, and Canada, where antibody performed unexpectedly well than ever seen elsewhere. However, side effects included swelling, pain, fever, headache, fatigue, joint &muscle aches, and redness at the site of injection. Around 2,000 Ebola-associated demises have been reported and the vaccine is injected to over 200,000 people in Congo, a country in Central Africa. Another study reporting the Ebola outbreak in Guinea concluded that the vaccine is considered 100% effective when injected in patients.
After grabbing approval, the EU is now heading towards mass production of the vaccine, known as V920, in Germany in the next year.
On a related note, Health Minister Saad Jaber and Amjad Adaileh, Minister of State for Media Affairs, organized a joint press conference last week to converse about swine flu (H1N1) infections. Several pharmaceutical companies noted that after the meeting, the demand for the flu vaccine has surged significantly. In the meeting, Jaber revealed the judgment finalized by the government of slashing the flu vaccine prices to 50%, pulling down the cost price from JD11 to JD5.5, on an average.
Based on the recent survey conducted by the Ministry of Health, the swine flu cases uplifted to 292, comprising nine demises. During an interview with The Jordan Times, Pulmonologist Ibrahim Al Aqeel stated that H1N1 infection led to death only in “very extreme cases.”